Toggle light / dark theme

Get the latest international news and world events from around the world.

Log in for authorized contributors

Cortical traveling waves in time and space: Physics, physiology, and psychology

The advent and widespread adoption of diverse widefield imaging techniques across multiple spatial resolutions has demonstrated that cortical activity often propagates as waves structured in both time and space. This realization allows neuroscientists to draw on a rigorous theoretical framework developed in wave physics to complement and inform the rapid neuroscientific advances shedding light on the physiological mechanisms and psychological implications of cortical wave dynamics. In support of this synthesis, we review some of the core concepts that underpin wave physics and consider how they relate to experimental studies of cortical wave physiology and psychology.

Carl David Anderson

Carl David Anderson was born in New York City, the son of Swedish immigrants. He studied physics and engineering at Caltech (B.S., 1927; Ph. D., 1930). Under the supervision of Robert Millikan, He began investigations into cosmic rays during the course of which he encountered unexpected particle tracks in his (modern versions now commonly referred to as an Anderson) cloud chamber photographs that he correctly interpreted as having been created by a particle with the same mass as the electron, but with opposite electrical charge. This discovery, announced in 1932 and later confirmed by others, validated Paul Dirac’s theoretical prediction of the existence of the positron. Anderson first detected the particles in cosmic rays. He then produced more conclusive proof by shooting gamma rays produced by the natural radioactive nuclide ThC’’ (208 Tl) [ 2 ] into other materials, resulting in the creation of positron-electron pairs. For this work, Anderson shared the 1936 Nobel Prize in Physics with Victor Hess. [ 3 ] Fifty years later, Anderson acknowledged that his discovery was inspired by the work of his Caltech classmate Chung-Yao Chao, whose research formed the foundation from which much of Anderson’s work developed but was not credited at the time. [ 4 ]

Also in 1936, Anderson and his first graduate student, Seth Neddermeyer, discovered a muon (or ‘mu-meson’, as it was known for many years), a subatomic particle 207 times more massive than the electron, but with the same negative electric charge and spin 1/2 as the electron, again in cosmic rays. Anderson and Neddermeyer at first believed that they had seen a pion, a particle which Hideki Yukawa had postulated in his theory of the strong interaction. When it became clear that what Anderson had seen was not the pion, the physicist I. I. Rabi, puzzled as to how the unexpected discovery could fit into any logical scheme of particle physics, quizzically asked “Who ordered that?” (sometimes the story goes that he was dining with colleagues at a Chinese restaurant at the time). The muon was the first of a long list of subatomic particles whose discovery initially baffled theoreticians who could not make the confusing “zoo” fit into some tidy conceptual scheme.

Big Tech’s Big Bet on AI Driving $344 Billion in Spend This Year

If there’s any lesson to take from the spending plans issued by the world’s largest technology companies over the past two weeks, it’s to never underestimate the fear of missing out.

Microsoft Corp., which set a $24.2 billion capital spending record last quarter, plans to drop upwards of $30 billion in the current period. Amazon.com Inc. similarly spent $31.4 billion last quarter, almost double what it dropped a year ago, and is maintaining that level of investment. Google owner Alphabet Inc. raised its capital expenditures guidance this year to $85 billion.

Novel radioimmunotherapy eradicates cancer stem cells in ovarian cancer model

A new radioimmunotherapy approach has been shown to successfully eliminate cancer stem cells (CSCs) in preclinical models of ovarian cancer, outperforming the current gold standard. This research, published in the July issue of The Journal of Nuclear Medicine, lays the foundation for further development of radionuclide therapies targeting CSCs, offering renewed hope for more effective treatment options and improved outcomes for patients.

CSCs are highly tumorigenic, self-renewable cells that play a key role in tumor relapse, metastasis, and resistance. Although the clinical significance of eliminating CSCs is clearly recognized and CSC immunotherapies have been examined in preclinical and clinical evaluations, the development of such therapies remains a challenge.

“Radioimmunotherapy enables precise, target-specific delivery of particulate radiation to cancer-associated antigens, while minimizing off-target accumulation and increasing tumor retention and irradiation, which makes it a promising choice for targeting CSCs,” stated Jürgen Grünberg, Ph.D., senior scientist at the Center for Radiopharmaceutical Sciences, Center for Life Sciences at the Paul Scherrer Institute in Villigen, Switzerland.

Researchers harness AI-powered protein design to enhance T-cell based immunotherapies

A paper published in Cell highlights how researchers have leveraged AI-based computational protein design to create a novel synthetic ligand that activates the Notch signaling pathway, a key driver in T-cell development and function.

These so-called soluble Notch agonists can be broadly applied to optimize clinical T-cell production and advance immunotherapy development.

Notch signaling is central to many cellular differentiation processes and is essential in transforming human immune cells into T-cells that target viruses and tumors. But activating Notch signaling in the laboratory has posed a challenge.